Evidence map›Paper›PMID 21212348›Full record

ReviewScience (New York, N.Y.)2011

Innate or adaptive immunity? The example of natural killer cells.

Eric Vivier, David H Raulet, Alessandro Moretta, Michael A Caligiuri, Laurence Zitvogel, Lewis L Lanier, Wayne M Yokoyama, Sophie Ugolini

Registry-linked trialAbstract readReview
In one paragraph

Review in Science (New York, N.Y.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04108936 (Longitudinal Study of the Effect of Cytoreductive Surgery and HIPEC in Patients With Peritoneal Carcinomatoses), which is not on this map. Cited by 1,506 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,506citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04108936 recruitingnot on this mapstarted 2016, after this paper: background citation

Longitudinal Study of the Effect of Cytoreductive Surgery and HIPEC in Patients With Peritoneal Carcinomatoses

TypeobservationalSponsorUniversity of RegensburgRan2016 to 2028Enrolled250ConditionsPeritoneal Carcinomatosis
3 · Its place in the literature

Who cites it

1,506 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Recent advances in CAR T and CAR NK cell therapy for AML.International journal of hematology · 2026
    Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Innate immunity: current understandings and future perspectives.Signal transduction and targeted therapy · 2026
    Review

1,446 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Eric VivierCentre d'Immunologie de Marseille-Luminy (CIML), Université de la Méditerranée UM 631, Campus de Luminy, 13288 Marseille, France. vivier@ciml.univ-mrs.fr
David H Raulet
Alessandro Moretta
Michael A Caligiuri
Laurence Zitvogel
Lewis L Lanier
Wayne M Yokoyama
Sophie Ugolini

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI WANCAI YANG · 1985 to 2026
$132.3M
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Monica Gandhi · 1988 to 2026
$93.6M
TWO SIGNAL REQUIREMENT FOR NATURAL KILLER IMMUNITYP01CA095426 · NCI · OHIO STATE UNIVERSITY · PI CARSON, WILLIAM E. · 2002 to 2016
$29.6M
NK MemoryR01AI068129 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LANIER, LEWIS LEE · 2006 to 2020
$6.0M
EXPRESSION OF CLASS I-SPECIFIC RECEPTORS IN NK CELLSR01AI039642 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI RAULET, DAVID H · 1996 to 2014
$4.9M
IL-15--CHARACTERIZATION THROUGH EXPERIMENTAL IMMUNOLOGYR01CA068458 · NCI · ROSWELL PARK CANCER INSTITUTE · PI CALIGIURI, MICHAEL A, YU, JIANHUA · 1996 to 2019
$4.5M
Specificity of Murine CMV Resistance by NK CellsR01AI051345 · NIAID · WASHINGTON UNIVERSITY · PI YOKOYAMA, WAYNE M. · 2002 to 2016
$4.5M
Role of NKG2D in immune responses to turmorsR01CA093678 · NCI · UNIVERSITY OF CALIFORNIA BERKELEY · PI RAULET, DAVID H · 2003 to 2019
$4.2M
INVIVO DEVELOPMENT OF NATURAL KILLER CELLSR01AI033903 · NIAID · WASHINGTON UNIVERSITY · PI YOKOYAMA, WAYNE M. · 1992 to 2015
$4.0M
NK and T Cell Costimulation by NKG2D/DAP10R37AI066897 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LANIER, LEWIS LEE · 2006 to 2015
$3.8M
RAE-1 Family of Proteins in Innate and Adaptive ImmunityR01CA095137 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LANIER, LEWIS LEE · 2003 to 2013
$2.9M
Activation Receptors on NK CellsR37AI034385 · NIAID · WASHINGTON UNIVERSITY · PI YOKOYAMA, WAYNE M. · 2002 to 2011
$2.6M
Howard Hughes Medical InstituteNCI NIH HHS CA093678NCI NIH HHS CA095137NCI NIH HHS CA16058NCI NIH HHS CA68458NCI NIH HHS CA95426NCI NIH HHS R01 CA093678NIAID NIH HHS AI035021NIAID NIH HHS AI039642NIAID NIH HHS AI066897NIAID NIH HHS AI068129NIAID NIH HHS AI33903NIAID NIH HHS AI34385NIAID NIH HHS AI51345NIAID NIH HHS AI5716NIAID NIH HHS P30 AI027763NIAID NIH HHS R01 AI035021NIAID NIH HHS R01 AI039642
6 · The paper itself

Abstract

Natural killer (NK) cells were originally defined as effector lymphocytes of innate immunity endowed with constitutive cytolytic functions. More recently, a more nuanced view of NK cells has emerged. NK cells are now recognized to express a repertoire of activating and inhibitory receptors that is calibrated to ensure self-tolerance while allowing efficacy against assaults such as viral infection and tumor development. Moreover, NK cells do not react in an invariant manner but rather adapt to their environment. Finally, recent studies have unveiled that NK cells can also mount a form of antigen-specific immunologic memory. NK cells thus exert sophisticated biological functions that are attributes of both innate and adaptive immunity, blurring the functional borders between these two arms of the immune response.

Indexed as

Adaptive ImmunityImmunity, InnateAnimalsHumansImmunologic MemoryKiller Cells, NaturalNeoplasmsReceptors, ImmunologicSelf ToleranceVirus DiseasesReceptors, Immunologic

Identifiers

PMID21212348
PMCPMC3089969

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.